ProShares UltraShort NASDAQ Biotechnology
9 hedge funds and large institutions have $4.07M invested in ProShares UltraShort NASDAQ Biotechnology in 2019 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 5 increasing their positions, 2 reducing their positions, and 2 closing their positions.
150% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 2
33% more capital invested
Capital invested by funds: $3.06M → $4.07M (+$1.01M)
0.38% more ownership
Funds ownership: 1.81% → 2.2% (+0.38%)
10% less funds holding
Funds holding: 10 → 9 (-1)
50% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$543K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$331K |
| 3 |
PAG
Private Advisor Group
Morristown,
New Jersey
|
+$273K |
| 4 |
HF
HRT Financial
New York
|
+$258K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$112K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
-$426K |
| 2 |
WP
WealthSource Partners
San Luis Obispo,
California
|
-$376K |
| 3 |
Morgan Stanley
New York
|
-$7.49K |
| 4 |
Simplex Trading
Chicago,
Illinois
|
-$5K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Citadel Advisors
Miami,
Florida
| $1.54M | +$543K | +3,700 | +63% |
|
|
WP
2
WealthSource Partners
San Luis Obispo,
California
| $1.02M | -$376K | -2,563 | -29% |
|
|
3
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $782K | +$331K | +2,252 | +86% |
|
|
HF
4
HRT Financial
New York
| $529K | +$258K | +1,758 | +114% |
|
|
TRCT
5
Tower Research Capital (TRC)
New York
| $129K | +$112K | +760 | +1,617% |
|
6
UBS Group
Zurich,
Switzerland
| $47K | +$30.2K | +206 | +229% |
|
|
7
Morgan Stanley
New York
| $11K | -$7.49K | -51 | -43% |
|
8
Citigroup
New York
| $7K | – | – | – |
|
|
PAG
9
Private Advisor Group
Morristown,
New Jersey
| $7K | +$273K | +1,856 | New |
|
|
BG
10
Bellevue Group
Kuesnacht,
Switzerland
| – | -$426K | -3,125 | Closed |
|
|
11
Simplex Trading
Chicago,
Illinois
| – | -$5K | -37 | Closed |
|
BIS Hedge Fund Activity: Q3 2019 in Review
9 of the 4,561 institutional investors tracked by Wall St. Rank reported a position in ProShares UltraShort NASDAQ Biotechnology (BIS) for Q3 2019, worth a combined $4.07M — up 33% from $3.06M a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of BIS and 1 opened new positions — a net loss of 1 holder — while 2 trimmed existing stakes and 5 added.
The largest buyer was Citadel Advisors, adding an estimated $543K. The largest seller was Bellevue Group, exiting entirely with an estimated $426K sold.
- 9 institutional investors held ProShares UltraShort NASDAQ Biotechnology (BIS) as of Q3 2019, down from 10 in Q2 2019.
- Funds reported $4.07M of ProShares UltraShort NASDAQ Biotechnology stock for Q3 2019, up 33% quarter-over-quarter.
- 1 fund opened new ProShares UltraShort NASDAQ Biotechnology positions in Q3 2019 and 2 closed out, a net change of -1 holder.
- The largest ProShares UltraShort NASDAQ Biotechnology buyer in Q3 2019 was Citadel Advisors, an estimated $543K added.
- The largest ProShares UltraShort NASDAQ Biotechnology seller in Q3 2019 was Bellevue Group, an estimated $426K sold.
Based on aggregated 13F filings for Q3 2019.